20
Mar
2023
Tag: clinical trials
7
Nov
2022
Bionest
Down to the Wire: The Race Between Amgen and Mirati for KRAS-Inhibitor Approvals
Who is ahead in the race for KRAS-inhibitor approval? We explore the latest drug development updates for sotorasib and adagrasib.
11
Apr
2022
Bionest
Use of Decentralized Trials Growing, But Barriers to Adoption Remain
Despite their benefits, decentralized clinical trials still face many barriers to widespread adoption. What will it take to overcome them?
28
Oct
2020
Bionest
Time to Embrace Decentralized Clinical Trials
A clearer roadmap for decentralized clinical trials will enable companies to better plan and more quickly advance their adoption of these strategies, which have the potential of benefiting patients and drug developers alike.
21
Oct
2019
Bionest
New Strategies Against a Hard-to-Treat Killer — Pancreatic Cancer
Pancreatic cancer was the third leading cause of cancer-related death in the United States in 2018. This year, experts estimate that 56,770 new cases will be diagnosed and 45,750 deaths will be recorded. Pancreatic cancer is especially lethal because in its early stages, when the disease is easiest to treat, patients are usually asymptomatic. The disease...
2
Sep
2019
Bionest
Zolgensma Launch “On Track,” but Significant Challenges Remain
On July 18, Novartis told analysts its Zolgensma launch was “on track.” Despite the gene therapy’s $2.1 million price tag, the company states the launch is “one of the most successful launches from an access standpoint in rare diseases.” Novartis said it had reached coverage deals with more than 20 commercial insurance plans, covering approximately 40%...
12
Aug
2019
Bionest
New Excitement About Antibody-Drug Conjugates in Cancer
The ability to target malignant cells without damage to surrounding healthy ones has been a long-sought goal in cancer drug development. Antibody-drug conjugates (ADCs) have been investigated as one such solution aimed at delivering more targeted therapies. ADCs — an approach first envisioned by Paul Ehrlich in the early 20th century — combine the targeting...
22
Jul
2019
Bionest
Real World Evidence Replacing Some Clinical Trials?
Pharmaceutical companies have long used real-world data on drug performance to help justify their pricing decisions to payers. But now such real-world evidence (RWE), gathered from electronic medical records (EMRs), national patient registries and other patient databases, is increasingly being looked at as a way to make the case for new supplemental approvals and label...
17
Jun
2019
Bionest
Highlights from AAN: Part 1
The Bionest team attended the American Academy of Neurology (AAN) in early May, where we heard exciting data presented in a number of neurological conditions. Among the highlights of this year’s conference: Transformative Success in Spinal Muscular Atrophy Spinal muscular atrophy (SMA) was a hot topic at AAN, with presentations of positive clinical...
10
Jun
2019